keyword
MENU ▼
Read by QxMD icon Read
search

"peptide receptor radionuclide therapy"

keyword
https://www.readbyqxmd.com/read/28957840/the-efficacy-of-the-available-peptide-receptor-radionuclide-therapy-for-neuroendocrine-tumors-a-meta-analysis
#1
Shorouk F Dannoon, Saud A Alenezi, Abdelhamid H Elgazzar
AIM: This study was carried out to compare the efficacy of Y, Lu, and combination of both radiotracers (tandem) peptide receptor radionuclide therapy (PRRT) in patients with inoperable and metastatic neuroendocrine tumors. MATERIALS AND METHODS: Systematic searches of PubMed and SciVerse Scopus databases were performed till December of 2016. The data were categorized into three groups: Y-PRRT, Lu-PRRT, and tandem-PRRT. Each group was subdivided on the basis of the response criteria used: Response Evaluation Criteria in Solid Tumors (RECIST) or Southwest Oncology Group (SWOG) criteria...
September 27, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28949122/role-of-positron-emission-tomography-in-thyroid-and-neuroendocrine-tumours
#2
Giorgio Treglia, Alexander S Kroiss, Arnoldo Piccardo, Filippo Lococo, Prasanna Santhanam, Alessio Imperiale
BACKGROUND: Positron emission tomography (PET) is an established imaging method in oncology. PET/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI) are hybrid techniques which combine morphological information obtained by CT and MRI with functional data provided by PET. Several radiotracers evaluating different metabolic pathways or receptor status can be used as PET radiotracers to assess endocrine tumours such as thyroid tumours or neuroendocrine neoplasms (NENs)...
September 25, 2017: Minerva Endocrinologica
https://www.readbyqxmd.com/read/28910148/bulk-scale-formulation-of-therapeutic-doses-of-clinical-grade-ready-to-use-177-lu-dota-tate-the-intricate-radiochemistry-aspects
#3
Anupam Mathur, Vrinda Prashant, Navin Sakhare, Sudipta Chakraborty, K V Vimalnath, Repaka Krishna Mohan, Chanda Arjun, Barkha Karkhanis, Ravi Seshan, Sandip Basu, Aruna Korde, Sharmila Banerjee, Ashutosh Dash, Satbir Singh Sachdev
INTRODUCTION: (177)Lu-DOTA-TATE is a clinically useful and promising therapeutic radiopharmaceutical for peptide receptor radionuclide therapy of neuroendocrine tumors (NETs) overexpressing somatostatin receptors. Currently, the radiopharmaceutical is prepared in-house at nuclear medicine centers, thereby restricting its use to limited centers only. In this article, the authors describe systematic studies toward bulk scale formulation of "ready-to-use" (177)Lu-DOTA-TATE using medium specific activity (177)Lu (740-1110 GBq/mg) at a centralized radiopharmacy facility...
September 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28902781/efficacy-of-peptide-receptor-radionuclide-therapy-in-a-united-states-based-cohort-of-metastatic-neuroendocrine-tumor-patients-single-institution-retrospective-analysis
#4
Bryson W Katona, Giorgio A Roccaro, Michael C Soulen, Yu-Xiao Yang, Bonita J Bennett, Brian P Riff, Rebecca A Glynn, Damian Wild, Guillaume P Nicolas, Daniel A Pryma, Ursina R Teitelbaum, David C Metz
OBJECTIVES: The aim of this study was to analyze in a retrospective cohort study the outcomes of a United States-based group of metastatic neuroendocrine tumor (NET) patients who underwent peptide receptor radionuclide therapy (PRRT). METHODS: Twenty-eight patients from a single US NET Center were treated with PRRT. Toxicities were assessed using Common Terminology Criteria for Adverse Events version 4.03. Progression was determined by the Response Evaluation Criteria in Solid Tumors version 1...
October 2017: Pancreas
https://www.readbyqxmd.com/read/28894897/peptide-receptor-radionuclide-therapy-prrt-in-european-neuroendocrine-tumour-society-enets-grade-3-g3-neuroendocrine-neoplasia-nen-a-single-institution-retrospective-analysis
#5
Sue Ping Thang, Mei Sim Lung, Grace Kong, Michael S Hofman, Jason Callahan, Michael Michael, Rodney J Hicks
PURPOSE: Grade 3 NENs are aggressive tumours with poor prognosis. PRRT+/- radiosensitising chemotherapy is a potential treatment for disease with high somatostatin receptor (SSTR) expression without spatially discordant FDG-avid disease. We retrospectively evaluated the efficacy of PRRT in G3 NEN. METHODS: Kaplan-Meier estimation was used to determine progression-free survival (PFS) and overall survival (OS) defined from start of PRRT. Subgroup analysis was performed for patients with Ki-67 ≤ 55% and >55%...
September 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28868578/management-of-pulmonary-neuroendocrine-tumors
#6
REVIEW
Robert A Ramirez, Aman Chauhan, Juan Gimenez, Katharine E H Thomas, Ioni Kokodis, Brianne A Voros
Neuroendocrine tumors (NETs) of the lung are divided into 4 major types: small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), atypical carcinoid (AC) or typical carcinoid (TC). Each classification has distinctly different treatment paradigms, making an accurate initial diagnosis essential. The inconsistent clinical presentation of this disease, however, makes this difficult. The objective of this manuscript is to detail the diagnosis and management of the well differentiated pulmonary carcinoid (PC) tumors...
September 4, 2017: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/28864881/improving-quality-of-life-in-patients-with-pancreatic-neuroendocrine-tumor-following-peptide-receptor-radionuclide-therapy-assessed-by-eortc-qlq-c30
#7
Milka Marinova, Martin Mücke, Lukas Mahlberg, Markus Essler, Henning Cuhls, Lukas Radbruch, Rupert Conrad, Hojjat Ahmadzadehfar
INTRODUCTION: Neuroendocrine tumors (NETs) have proven to be appropriate neoplasms for peptide receptor radionuclide therapy (PRRT), as the majority of these slow-growing malignancies overexpress somatostatin receptors. The aim of this study was to evaluate changes in quality of life (QoL) of patients with P-NET following PRRT. METHODS: Sixty-eight patients with P-NET (31 female, mean age 61.4 y) underwent PRRT: 12 with NET of grade 1, 40 of grade 2, 8 of grade 3 (grade non-available n = 8)...
September 1, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28864620/individualized-dosimetry-for-theranostics-necessary-nice-to-have-or-counterproductive
#8
REVIEW
Uta Eberlein, Marta Cremonesi, Michael Lassmann
In 2005, the term theragnostics (theranostics) was introduced for describing the use of imaging for therapy planning in radiation oncology. In nuclear medicine, this expression describes the use of tracers for predicting the absorbed doses in molecular radiotherapy and, thus, the safety and efficacy of a treatment. At present, the most successful groups of isotopes for this purpose are (123)I/(124)I/(131)I, (68)Ga/(177)Lu, and (111)In/(86)Y/(90)Y. The purpose of this review is to summarize available data on the dosimetry and dose-response relationships of several theranostic compounds, with a special focus on radioiodine therapy for differentiated thyroid cancer and peptide receptor radionuclide therapy...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864614/somatostatin-receptor-antagonists-for-imaging-and-therapy
#9
REVIEW
Melpomeni Fani, Guillaume P Nicolas, Damian Wild
Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been used for more than 20 y. An important improvement in recent years was the introduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, such as [(90)Y-DOTA(0),Tyr(3)]octreotide or [(177)Lu-DOTA(0),Tyr(3)]octreotide ((90)Y- or (177)Lu-DOTATOC, respectively) and [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE). PET/CT with (68)Ga-labeled sstr agonists, such as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)Ga-DOTANOC), plays an important role in staging and restaging neuroendocrine tumors...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864613/somatostatin-receptor-2-targeting-compounds
#10
REVIEW
Daan A Smit Duijzentkunst, Dik J Kwekkeboom, Lisa Bodei
The molecular imaging and treatment of neuroendocrine tumors (NETs) with radiolabeled somatostatin analogs represent a milestone in the development of theranostic compounds. Whole-body scintigraphy with (111)In-pentetreotide has revolutionized the diagnosis and staging of NETs and the evaluation of treatment outcomes. At present, diagnostic accuracy with positron-emitting radionuclides is greater than 90%. Peptide receptor radionuclide therapy (PRRT) has become a well-accepted treatment for patients with well-differentiated inoperable or metastatic NETs and disease progression after first-line treatment...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28864612/clinical-history-of-the-theranostic-radionuclide-approach-to-neuroendocrine-tumors-and-other-types-of-cancer-historical-review-based-on-an-interview-of-eric-p-krenning-by-rachel-levine
#11
Rachel Levine, Eric P Krenning
In nuclear medicine, the term theranostics describes the combination of therapy and diagnostic imaging. In practice, this concept dates back more than 50 years; however, among the most successful examples of theranostics are peptide receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine tumors. The development of these modalities through the radiolabeling of somatostatin analogs with various radionuclides has led to a revolution in patient management and established a foundation for expansion of the theranostic principle into other oncology indications...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28832377/safety-and-effectiveness-of-177lu-dotatate-peptide-receptor-radionuclide-therapy-after-regional-hepatic-embolization-in-patients-with-somatostatin-expressing-neuroendocrine-tumors
#12
Mohammadali Hamiditabar, Muzammil Ali, Luke Bolek, Gelareh Vahdati, Izabela Tworowska, Ebrahim S Delpassand
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE is shown to be an effective therapeutic option for somatostatin-expressing neuroendocrine neoplasms. Some concerns are raised over safety of this modality in patients with a history of regional chemoembolization and radionuclide hepatic embolization (CRHE) and is cause of reluctance among some physicians for suggesting Lu-DOTATATE in this patient population. METHODS: We retrospectively reviewed 143 patients with somatostatin-expressing neuroendocrine tumors who underwent Lu-DOTATATE PRRT...
November 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28831446/identifying-and-prioritizing-gaps-in-neuroendocrine-tumor-research-a-modified-delphi-process-with-patients-and-health-care-providers-to-set-the-research-action-plan-for-the-newly-formed-commonwealth-neuroendocrine-tumor-collaboration
#13
Eva Segelov, David Chan, Ben Lawrence, Nick Pavlakis, Hagen F Kennecke, Christopher Jackson, Calvin Law, Simron Singh
PURPOSE: Neuroendocrine tumors (NETs) are a diverse group of malignancies that pose challenges common to all rare tumors. The Commonwealth Neuroendocrine Tumor Collaboration (CommNETS) was established in 2015 to enhance outcomes for patients with NETs in Canada, Australia, and New Zealand. A modified Delphi process was undertaken involving patients, clinicians, and researchers to identify gaps in NETs research to produce a comprehensive and defensible research action plan. METHODS: A three-round modified Delphi process was undertaken with larger representation than usual for medical consensus processes...
August 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28804185/somatostatin-analogues-labeled-with-copper-radioisotopes-current-status
#14
REVIEW
Aleksandra Marciniak, Justyna Brasuń
Peptide receptor radionuclide therapy (PRRT) is a promising way to treat patients with inoperable tumors or metastatic neuroendocrine tumors. This therapeutic strategy is using radiolabeled peptides, which are capable of selective biding to receptors overexpressed in the cancer cells. One of the group of receptor-avid peptide used in the PRRT are the analogues of somatostatin (SST) connected to the complexes of radionuclides (e.g. (90)Y, (177)Lu or (111)In). Many studies have shown that radiopharmaceuticals based on Cu radioisotopes are promising for the diagnosis and treatment of various cancers...
2017: Journal of Radioanalytical and Nuclear Chemistry
https://www.readbyqxmd.com/read/28798226/image-guided-combination-of-177-lu-dotatate-and-capecitabine-peptide-receptor-chemoradionuclide-therapy-in-metastatic-mediastinal-paraganglioma
#15
Abhiram G Ashwathanarayana, Chinmoy K Biswal, Ashwani Sood, Ashwin S Parihar, Rakesh Kapoor, Bhagwant R Mittal
The peptide receptor radionuclide therapy (PRRT) targets highly expressed somatostatin receptors (SSTR) shown on SSTR imaging in well-differentiated neuroendocrine tumours (NETs) with stable or partial response in majority of inoperable/metastatic NETs patients. However NETs showing increased FDG uptake carry the poor outcome with limited treatment options and role of PRRT is still unclear. Here is a case of young male patient of mediastinal paraganglioma and extensive metastatic disease showing avidity both on SSTR and FDG imaging...
August 10, 2017: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/28775205/therapy-related-hematological-malignancies-after-peptide-receptor-radionuclide-therapy-with-177-lu-dota-octreotate-incidence-course-predicting-factors-in-patients-with-gep-nets
#16
Hendrik Bergsma, Kirsten van Lom, Mark Konijnenberg, Boen Kam, Jaap Teunissen, Wouter de Herder, Eric Krenning, Dik Kwekkeboom
Peptide Receptor Radionuclide Therapy (PRRT) may induce long-term toxicity to the bone marrow (BM). The aim of this study was to analyze persistent dysfunction of the hematopoietic system after PRRT with (177)Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: The incidence and course of persistent hematological dysfunction (PHD) was analyzed in 274 (=GEP-NET) out of 367 patients with somatostatin receptor-positive tumors. PHD was defined as diagnosis of Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (MPN), Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN) or otherwise unexplained cytopenia (for more than 6 months)...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28744319/-177-lu-pentixather-comprehensive-preclinical-characterization-of-a-first-cxcr4-directed-endoradiotherapeutic-agent
#17
Margret Schottelius, Theresa Osl, Andreas Poschenrieder, Frauke Hoffmann, Seval Beykan, Heribert Hänscheid, Andreas Schirbel, Andreas K Buck, Saskia Kropf, Markus Schwaiger, Ulrich Keller, Michael Lassmann, Hans-Jürgen Wester
Purpose: Based on the clinical relevance of the chemokine receptor 4 (CXCR4) as a molecular target in cancer and on the success of [(68)Ga]pentixafor as an imaging probe for high-contrast visualization of CXCR4-expression, the spectrum of clinical CXCR4-targeting was expanded towards peptide receptor radionuclide therapy (PRRT) by the development of [(177)Lu]pentixather. Experimental design: CXCR4 affinity, binding specificity, hCXCR4 selectivity and internalization efficiency of [(177)Lu]pentixather were evaluated using different human and murine cancer cell lines...
2017: Theranostics
https://www.readbyqxmd.com/read/28739329/peptide-receptor-radionuclide-therapy-induced-gitelman-like-syndrome
#18
Aurelio Negro, Giovanni M Rossi, Davide Nicoli, Annibale Versari, Enrico Farnetti, Rosaria Santi, Stefano De Pietri
Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function...
July 21, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/28739143/prediction-of-time-integrated-activity-coefficients-in-prrt-using-simulated-dynamic-pet-and-a-pharmacokinetic-model
#19
Deni Hardiansyah, Ali Asgar Attarwala, Peter Kletting, Felix M Mottaghy, Gerhard Glatting
PURPOSE: To investigate the accuracy of predicted time-integrated activity coefficients (TIACs) in peptide-receptor radionuclide therapy (PRRT) using simulated dynamic PET data and a physiologically based pharmacokinetic (PBPK) model. METHODS: PBPK parameters were estimated using biokinetic data of 15 patients after injection of (152±15)MBq of (111)In-DTPAOC (total peptide amount (5.78±0.25)nmol). True mathematical phantoms of patients (MPPs) were the PBPK model with the estimated parameters...
July 21, 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28732021/in-vitro-comparison-of-213bi-and-177lu-radiation-for-peptide-receptor-radionuclide-therapy
#20
COMPARATIVE STUDY
Ho Sze Chan, Erik de Blois, Alfred Morgenstern, Frank Bruchertseifer, Marion de Jong, Wouter Breeman, Mark Konijnenberg
BACKGROUND: Absorbed doses for α-emitters are different from those for β-emitters, as the high linear energy transfer (LET) nature of α-particles results in a very dense energy deposition over a relatively short path length near the point of emission. This highly localized and therefore high energy deposition can lead to enhanced cell-killing effects at absorbed doses that are non-lethal in low-LET type of exposure. Affinities of DOTA-DPhe1-Tyr3-octreotate (DOTATATE), 115In-DOTATATE, 175Lu-DOTATATE and 209Bi-DOTATATE were determined in the K562-SST2 cell line...
2017: PloS One
keyword
keyword
108898
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"